Last reviewed · How we verify

Nisreen Ibrahim khan — Portfolio Competitive Intelligence Brief

Nisreen Ibrahim khan pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Nano Silver Fluoride varnish Nano Silver Fluoride varnish marketed
nano-hydroxyapatite varnish nano-hydroxyapatite varnish marketed Remineralizing agent Tooth enamel (hydroxyapatite crystal structure) Dentistry / Oral Health
sodium Fluoride Varnish sodium Fluoride Varnish marketed Topical fluoride agent Hydroxyapatite in tooth enamel and dentin; bacterial glycolytic enzymes Dentistry / Preventive Oral Health

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. CareQuest Institute for Oral Health · 1 shared drug class
  3. Gaba International AG · 1 shared drug class
  4. GlaxoSmithKline · 1 shared drug class
  5. Hadassah Medical Organization · 1 shared drug class
  6. King Abdulaziz University · 1 shared drug class
  7. Procter and Gamble · 1 shared drug class
  8. Riyadh Colleges of Dentistry and Pharmacy · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nisreen Ibrahim khan:

Cite this brief

Drug Landscape (2026). Nisreen Ibrahim khan — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nisreen-ibrahim-khan. Accessed 2026-05-16.

Related